3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
LipoScience's 3-Year ROIIC % for the quarter that ended in Dec. 2013 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for LipoScience's 3-Year ROIIC % or its related term are showing as below:
FRA:LI0's 3-Year ROIIC % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -8.22 * Ranked among companies with meaningful 3-Year ROIIC % only.
LipoScience 3-Year ROIIC % Historical Data
The historical data trend for LipoScience's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of LipoScience's 3-Year ROIIC %
For the Diagnostics & Research subindustry, LipoScience's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LipoScience's 3-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, LipoScience's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where LipoScience's 3-Year ROIIC % falls into.
LipoScience 3-Year ROIIC % Calculation
LipoScience's 3-Year ROIIC % for the quarter that ended in Dec. 2013 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -7.796 (Dec. 2013) - 3.0923997 (Dec. 2010) )
/
( 22.794 (Dec. 2013) - 4.675 (Dec. 2010) )
=
-10.8883997
/
18.119
=
-60.09%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
LipoScience (FRA:LI0) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
LipoScience 3-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of LipoScience's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LI0 has been successfully added to your 